Stroke Trials

Does extended head-to-heart CT angiography increase detection of cardioaortic thrombus in acute stroke or TIA without delaying treatment?

Does targeted training of the ipsilesional (less impaired) arm improve motor performance in chronic stroke patients with severe contralesional arm paresis?

Does a BCI intervention using the ReHand-BCI system with robotic hand orthosis feedback produce greater upper extremity motor recovery and neuroplastic changes compared to a sham-BCI intervention in stroke patients with hand paresis?

Can cervical epidural spinal cord stimulation safely and effectively improve motor function and reduce spasticity in individuals with chronic post-stroke upper-limb hemiparesis?

What are the long-term effects (through 12 months) of vagus nerve stimulation (VNS) paired with rehabilitation on impairment, activity, and participation in people with upper extremity (UE) impairment after chronic ischemic stroke?

Does glenzocimab, a platelet GPVI antagonist, improve functional outcomes when added to IV thrombolysis (± thrombectomy) in acute ischemic stroke?

Does IV tirofiban added after an inadequate response to tenecteplase improve 90-day functional outcomes in stroke patients without large vessel occlusion or cardioembolic source?

Does adding intravenous tenecteplase before thrombectomy improve functional independence at 90 days in patients with acute ischemic stroke due to large-vessel occlusion?

Does left atrial appendage closure safely decrease the risk of bleeding associated with oral anticoagulants while maintaining a low risk of stroke among patients with atrial fibrillation who have undergone catheter ablation and are at moderate or high risk for stroke?

Does intravenous tenecteplase administered within 4.5 hours of symptom onset improve visual outcomes compared to oral aspirin in patients with acute central retinal artery occlusion?

To determine whether time to treatment influences the effect of intraarterial thrombolysis (IAT), intravenous thrombolysis (IVT), and conservative standard therapy (CST) on visual outcomes in nonarteritic central retinal artery occlusion (CRAO).

Does tirzepatide improve obstructive sleep apnea severity and associated complications in adults with moderate-to-severe OSA and obesity?

Does lepodisiran, an siRNA targeting hepatic production of lipoprotein(a), safely and effectively reduce serum lipoprotein(a) concentrations over time?

Does starting amantadine early — before dyskinesia develops — cut the risk of levodopa-induced dyskinesia in Parkinson's disease?

What are the complication rates of carotid artery stenting (CAS) when performed by fellowship-trained neurointerventionalists (NIRs)?

In patients with acute ischemic stroke undergoing endovascular thrombectomy under general anesthesia, does early extubation (<6 hours) improve 90-day functional outcomes compared with delayed extubation (6-12 hours)?

Does staged bilateral MRgFUS thalamotomy provide meaningful and sustained tremor reduction — including midline tremor — with an acceptable safety profile in essential tremor patients who previously underwent unilateral treatment?

Does adding middle meningeal artery embolization to surgery reduce chronic subdural hematoma recurrence?

Is combination antithrombotic therapy superior to aspirin alone for intracranial atherosclerotic disease?

Does revascularization reduce stroke risk when added to optimized medical therapy in patients with asymptomatic or low-to-intermediate risk symptomatic carotid stenosis?

Can high-resolution MRI track the effect of intensive statins on intracranial plaque after ischemic stroke?

Among patients with asymptomatic high-grade carotid stenosis, does adding carotid revascularization (stenting or endarterectomy) to intensive medical management provide greater benefit than intensive medical management alone in preventing stroke?

Is IV tenecteplase plus endovascular thrombectomy (TNK + EVT) associated with better 3-month functional outcomes compared with EVT alone in patients with anterior circulation LVO stroke treated within 4.5 hours, and does any benefit vary with expected onset-to-thrombolysis time or admission center type?

In patients with recent noncardioembolic ischemic stroke or high-risk TIA on antiplatelet therapy, does asundexian 50 mg once daily (an activated factor XI inhibitor) reduce the risk of recurrent stroke compared with placebo?

Are direct oral anticoagulants (DOACs) as safe and effective as vitamin K antagonists (VKAs) for the treatment of cerebral venous thrombosis?

What are the outcomes and predictors of decompressive surgery in patients with severe cerebral venous thrombosis (CVT)?

Does minocycline, in addition to routine treatment, improve 90-day functional outcomes compared with placebo in patients with acute ischaemic stroke presenting within 72 hours of symptom onset?

In patients with acute LVO stroke without atrial fibrillation or intracardiac thrombus, which cardiac CT findings are independently associated with a cardioembolic stroke aetiology?

Does loberamisal, a dual-acting neuroprotective agent, improve functional recovery when administered within 48 hours of moderate to severe acute ischemic stroke?

Is off-label intravenous thrombolysis safe and effective in patients with acute ischemic stroke who have recently taken direct oral anticoagulants? Does DOAC reversal with idarucizumab before IVT improve safety or efficacy outcomes?

Does middle meningeal artery (MMA) embolization reduce the rate of chronic subdural hematoma (CSDH) recurrence in patients who underwent an operation and are at high risk of recurrence?

Can a simple clinical score predict which ESUS patients will develop atrial fibrillation on long-term implantable cardiac monitoring?

Does the oral PCSK9 inhibitor enlicitide effectively lower LDL cholesterol levels compared to placebo in adults with established atherosclerotic cardiovascular disease or at high risk for a first ASCVD event?

In AF patients at high risk for both stroke and bleeding, is catheter-based LAA closure noninferior to physician-directed best medical care (predominantly DOACs) for a composite of stroke, systemic embolism, major bleeding, or cardiovascular/unexplained death?

Does routine use of cerebral embolic protection (CEP) during transcatheter aortic-valve implantation (TAVI) reduce the incidence of stroke within 72 hours after the procedure?

Can the PASCAL classification system identify which patients with PFO and cryptogenic stroke will experience net benefit versus net harm from transcatheter PFO closure?

Does clazosentan (15 mg/hour IV), an endothelin receptor antagonist, reduce clinical deterioration due to delayed cerebral ischemia when administered for up to 14 days alongside standard care (including nimodipine) in patients with aneurysmal subarachnoid hemorrhage and thick diffuse clot?

Is galantamine safe, tolerable, and potentially efficacious in improving long-term functional and cognitive outcomes in patients with aneurysmal subarachnoid hemorrhage when administered during early and subacute stages?

Does a liberal red-cell transfusion strategy, as compared with a restrictive strategy, result in a lower risk of an unfavorable neurologic outcome at 12 months in critically ill adults with acute aneurysmal subarachnoid hemorrhage and anemia?

Does recombinant factor VIIa given within 2 hours of ICH onset improve functional outcomes compared to placebo?

Does middle meningeal artery embolisation (MMAe) reduce the composite of surgical drainage need, poor clinical outcome, or clinical deterioration compared to observation alone in mildly symptomatic chronic subdural haematoma patients?

To compare the safety and efficacy of minimally invasive surgery with the Artemis Neuro Evacuation Device to guideline-based medical management alone for spontaneous supratentorial intracerebral hemorrhage (ICH).

Can a single triple-combination blood pressure pill after ICH cut the risk of another stroke?

Does intensive systolic blood pressure reduction below 130–140 mmHg after successful mechanical thrombectomy improve functional outcomes compared to standard blood pressure management in acute ischemic stroke?

Does adding endovascular treatment to best medical treatment reduce disability or death at 12 months in patients with medium or distal vessel occlusion stroke?

In patients with proximal MCA occlusion presenting 4.5–24 hours after stroke onset who have direct access to EVT, does bridging intravenous tenecteplase improve functional outcomes compared to EVT alone?

Does nerinetide improve functional outcomes in patients with large vessel occlusion stroke undergoing endovascular thrombectomy who have not received prior thrombolysis?

Does thrombectomy improve functional outcomes compared to medical management alone in patients with medium vessel occlusion stroke and moderate-to-severe deficits (NIHSS ≥6) presenting within 24 hours?

Can rivaroxaban prevent cognitive decline in AF patients too low-risk for standard anticoagulation?